Grants per year
Personal profile
Training Experience
| 2003 | Residency, Royal College of Physicians, Ireland |
| 2009 | Fellowship, University of Texas Health Science Center, San Antonio |
| 2009 | Fellowship, Royal College of Physicians, Ireland |
Education/Academic qualification
PhD, National University of Ireland
… → 2009
MBBChBAO, National University of Ireland
… → 2000
Fingerprint Dive into the research topics where Devalingam Mahalingam is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 10 Similar Profiles
Neoplasms
Medicine & Life Sciences
Apoptosis
Medicine & Life Sciences
gemcitabine
Medicine & Life Sciences
Prostatic Neoplasms
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
TNF-Related Apoptosis-Inducing Ligand Receptors
Medicine & Life Sciences
Colorectal Neoplasms
Medicine & Life Sciences
Safety
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Grants 2017 2022
- 9 Active
Prot #19774: A multicenter Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of the combination of rogaratinib and copanlisib in patients with FGFR-positive, local
Bayer HealthCare Pharmaceuticals, Inc.
10/18/18 → 5/19/21
Project: Research project
Research Output 2008 2019
Heightened JNK activation and reduced XIAP levels promote TRAIL and sunitinib-mediated apoptosis in colon cancer models
Mahalingam, D., Carew, J. S., Espitia, C. M., Cool, R. H., Giles, F. J., De Jong, S. & Nawrocki, S. T., Jul 1 2019, In : Cancers. 11, 7, 895.Research output: Contribution to journal › Article
Open Access
X-Linked Inhibitor of Apoptosis Protein
Colonic Neoplasms
Phosphotransferases
Apoptosis
Neoplasms
Phase 1 open-label, multicenter study of first-in-class RORγ agonist LYC-55716 (Cintirorgon): Safety, tolerability, and preliminary evidence of antitumor activity
Mahalingam, D., Wang, J. S., Hamilton, E. P., Sarantopoulos, J., Nemunaitis, J., Weems, G., Carter, L., Hu, X., Schreeder, M. & Wilkins, H. J., Jun 15 2019, In : Clinical Cancer Research. 25, 12, p. 3508-3516 9 p.Research output: Contribution to journal › Article
Open Access
Multicenter Studies
Safety
Pharmacokinetics
Anemia
Hypophosphatemia
Prognosticating Survival in Hepatocellular Carcinoma with Elevated Baseline Alpha-fetoprotein Treated with Radioembolization Using a Novel Laboratory Scoring System: Initial Development and Validation
Ali, R., Yang, Y., Antkowiak, M., Gabr, A., Mora, R., Abouchaleh, N., Al Asadi, A., Kulik, L. M., Ganger, D. R., Abecassis, M. M., Kataraya, N., Mulcahy, M. F., Benson III, A. B., Mahalingam, D., Thornburg, B., Mouli, S. K., Lewandowski, R. J., Salem, R. & Riaz, A., Jan 1 2019, In : Cardiovascular and Interventional Radiology.Research output: Contribution to journal › Article
alpha-Fetoproteins
Hepatocellular Carcinoma
Survival
Research Ethics Committees
ROC Curve
10
Citations
(Scopus)
A phase ii study of pelareorep (REOLYSIN®) in combination with gemcitabine for patients with advanced pancreatic adenocarcinoma
Mahalingam, D., Goel, S., Aparo, S., Arora, S. P., Noronha, N., Tran, H., Chakrabarty, R., Selvaggi, G., Gutierrez, A., Coffey, M., Nawrocki, S. T., Nuovo, G. & Mita, M. M., Jun 1 2018, In : Cancers. 10, 6, 160.Research output: Contribution to journal › Article
gemcitabine
Adenocarcinoma
Oncolytic Virotherapy
Mammalian orthoreovirus 3
Survival Rate
Case report of prostate ductal adenocarcinoma presenting with hematuria
Pawlowski, J., Swanson, G. P., Mahalingam, D. & Ha, C. S., Jul 1 2018, In : Urology Case Reports. 19, p. 63-64 2 p.Research output: Contribution to journal › Article
Hematuria
Prostate
Adenocarcinoma